Plain-English translation of NCT03026140 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether giving patients immune-boosting medications—including and relatlimab—before colon cancer surgery can help prevent the cancer from coming back. The study includes different treatment combinations tailored to the specific characteristics of each patient's tumor. Researchers are exploring which combinations work best and are safest for people with early-stage colon cancer.
Early colon cancer can sometimes return even after surgery, and doctors want better ways to prevent that from happening. This medication approach works by helping your body's immune system recognize and attack cancer cells before they are removed by surgery.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous infusions of the study medications on specific days over several weeks, followed by colon cancer surgery within 10 to 12 weeks. Your treatment group would depend on the genetic characteristics of your tumor. You would have regular clinic visits for blood tests, imaging scans, and physical exams to monitor how the treatment is working and watch for any side effects.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Netherlands